Vyacheslav A Chubenko

  • Citations Per Year
Learn More
Development of malignancies in BRCA1 germ-line mutation carriers usually involves somatic inactivation of the remaining BRCA1 allele. This feature leads to a tumor-specific deficiency of double-strand DNA break repair and underlies pronounced sensitivity of BRCA1-driven cancers to cisplatin. BRCA1-specific activity of cisplatin has been repeatedly(More)
i. M. Negwer, Organisch-chemische Arzneimittel und ihre Synonyma, Berlin (1967). 2. A. N. Grinev, V. I. Shvedov, A. A. Stolyarchuk, et al., Khim. Farm. Zh., No. 6, 142 (1977) . 3. E. B i s a g n i and R. Royer, B u l l . Chem. Soc. F r . , 925 (1962) . 4. A. N. Grinev, S. A. Zotova, A. A. Stolyarchuk, et al., Khim. Farm, Zh., No. !, 51 ( 1 9 7 9 ) . 5. R.(More)
Gemcitabine is known to exert a therapeutic effect on brain tumors despite the limited permeability of the blood-brain barrier (BBB). In our experimental research single intraperitoneal (i.p.) injection of gemcitabine 25 mg/kg provided increase in median survival of mice with intracranially transplanted Ehrlich carcinoma by 41-89% (p < 0.001). In this(More)
We have previously reported [i] the synthesis and biological activity of 1,3,5-thiadiazolyloxamicacidamides. We established that the hypoglycemic and antibacterial activity depend on the character of the substituents bonded to the amide nitrogen atom. It seemed of interest to obtain new derivatives of oxamic acid, viz., N-beteryloxamic acid hydrazones, and(More)
Ovarian carcinomas (OC) arising in BRCA1 and BRCA2 mutation carriers demonstrate pronounced sensitivity to platinum-based therapy due to deficiency of double-strand break DNA repair. However, the choice of subsequent treatment lines for this category of women remains complicated. We considered mitomycin C for heavily pretreated hereditary OC patients, based(More)
Discovery of activating EGFR mutations led to dramatic modification of treatment schemes for nonsquamous lung cancer. 70 patients with activating EGFR mutations were treated by gefitinib being either a part of prospective phase II trial (n = 25) or, subsequently, subjected to routine clinical management (n = 45). Objective response rate approached to 32.7%.(More)
The absolute sensitivity signs of breast cancer to the drug have not yet been developed. Data from clinical trials on the study of experimental laboratory predictive markers of chemosensitivity: TOP2alpha (topoisomerase 2-alpha), beta-tubulin (subunit of dimeric protein tubulin), and BRCA1 (breast cancer 1) are contradictory and not numerous. Analysis of(More)
BACKGROUND Discontinuation of gefitinib treatment is often accompanied by a disease flare. Some studies have demonstrated a benefit of the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) beyond progression; however, long-term results of these investigations remain limited. PATIENTS AND METHODS We observed 70 patients with(More)